This trial will test if VTX2735 is safe/effective for treating Cryopyrin-Associated Period Syndrome (CAPS) in 10 patients, over a max of 4 weeks.
- Cryopyrin-Associated Periodic Syndromes (CAPS)
1 Primary · 5 Secondary · Reporting Duration: From Day 1 to completion of treatment with VTX2735, up to Day 28
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
10 Total Participants · 2 Treatment Groups
Primary Treatment: Cohort 1 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How likely are individuals to experience adverse effects when participating in Cohort 1?
"Since Cohort 1 is currently being trialled in Phase 2, our team at Power has estimated its safety to be a score of 2. This rating indicates that there are data that support the drug's security, but no evidence indicating how effective it may be." - Anonymous Online Contributor
Is recruitment for this research project still taking place?
"Affirmative, the information hosted on clinicaltrials.gov indicates that this research project is currently looking for participants. Initially posted on March 18th 2023, and recently updated in April 11th of the same year; 10 patients will be accepted from two specific locations." - Anonymous Online Contributor
How many participants are engaged in this research?
"Affirmative. Information accessed via clinicaltrials.gov reveals that this research endeavour, which was originally posted on March 18th 2023, is currently enrolling participants. The investigation desires 10 patients to be recruited from 2 distinct medical facilities." - Anonymous Online Contributor